Competitive Intelligence Tracker - FluxAI Healthcare Demo

Competitive Intelligence Tracker

Monitor research activity and strategic directions across organizations

AI Research Assistant

What competitive intelligence would you like to analyze today?

Organization Research Focus

Publications
Patents
Grants

Focus Areas:

Oncology Neurology Cardiology Immunology + Add

AI Insight:

NeuroCorp has shifted 40% of research from general neurology to Alzheimer's disease in the past 6 months, suggesting a strategic pivot.

Research Velocity

Company Logo Pfizer
+24%
Company Logo Novartis
+12%
Company Logo Merck
-5%
Company Logo Roche
+16%
Company Logo Sanofi
+8%

Researcher Network

Network visualization loading...

AI analyzing collaboration patterns...

Dr. Robert Chen

Stanford University

Research Focus: Immuno-oncology
Publications: 42 (last 2 years)
Key Collaborators: 16 researchers
Industry Partners: Roche, Novartis

AI Analysis:

Recent shift to CAR-T cell therapy research suggests alignment with Novartis strategic direction.

Patent Activity

247

New patents (last 30 days)

+18%

vs previous period

Top Patent Categories

Targeted Therapies 32%
Diagnostic Methods 24%
Delivery Systems 18%

Collaboration Patterns

Emerging Collaborations

Roche + Oxford University

New joint lab for AI-driven drug discovery

Pfizer + Mayo Clinic

Expanded partnership on digital biomarkers

Novartis + MIT

$25M funding for biomaterials research

Collaboration Strength

AI Pattern Recognition

Cross-sector collaborations in immunotherapy have increased by 35% in the last quarter, with most partnerships focusing on combination approaches that pair targeted therapies with checkpoint inhibitors.

Strategic Direction Predictor

AI-Powered Prediction

Based on 3,421 research papers, 856 patents, and funding data

Company Logo Novartis
87% confidence

Predicted to shift focus toward cell therapy manufacturing solutions within 6-12 months based on patent activity and talent acquisition patterns.

Company Logo Roche
92% confidence

Research pattern suggests major investments in liquid biopsy technology for early cancer detection, with likely announcement of clinical trials in Q3.

Company Logo Merck
78% confidence

Publication pattern indicates renewed focus on antibiotic resistance with potential expansion of antimicrobial research division.